Case Reports
Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect
Affiliations
- PMID: 12725337
Item in Clipboard
Case Reports
Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect
J Exp Clin Cancer Res.
2003 Mar.
Abstract
The regimen with paclitaxel and platinum compound (carboplatin or cisplatin) is the standard chemotherapy for patients with advanced ovarian cancer. Ototoxity for carboplatin and paclitaxel alone or combined is rarely observed. We report the case of a 35-year old female with advanced ovarian cancer who developed sudden bilateral sensorineural hearing loss related to paclitaxel and carboplatin based chemotherapy. This uncommon adverse effect of carboplatin and paclitaxel alone or combined is discussed and the literature reviewed. Hearing monitoring should be mandatory to evaluate the real incidence of clinical and sub-clinical hearing modification induced by carboplatin and paclitaxel based chemotherapy.
Similar articles
-
[Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].Praxis (Bern 1994). 1999 Mar 18;88(12):513-8. Praxis (Bern 1994). 1999. PMID: 10235026 Review. German.
-
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.Eur J Cancer. 2008 Oct;44(15):2169-77. doi: 10.1016/j.ejca.2008.06.035. Epub 2008 Aug 6. Eur J Cancer. 2008. PMID: 18691879 Clinical Trial.
-
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.J Clin Oncol. 2006 Feb 1;24(4):579-86. doi: 10.1200/JCO.2005.02.4067. J Clin Oncol. 2006. PMID: 16446330 Clinical Trial.
-
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.Gynecol Oncol. 2008 Apr;109(1):33-8. doi: 10.1016/j.ygyno.2008.01.001. Epub 2008 Feb 7. Gynecol Oncol. 2008. PMID: 18261784
-
Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature.Anticancer Res. 2005 May-Jun;25(3c):2509-13. Anticancer Res. 2005. PMID: 16080485 Review.
Cited by
-
Silibinin and Paclitaxel Cotreatment Significantly Suppress the Activity and Lung Metastasis of Triple Negative 4T1 Mammary Tumor Cell in Mice.J Tradit Complement Med. 2012 Oct;2(4):301-11. doi: 10.1016/s2225-4110(16)30116-x. J Tradit Complement Med. 2012. PMID: 24716145 Free PMC article.
-
Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.Eur J Oncol Nurs. 2018 Feb;32:1-11. doi: 10.1016/j.ejon.2017.10.006. Epub 2017 Nov 7. Eur J Oncol Nurs. 2018. PMID: 29353626 Free PMC article.
-
Cancer survivors and neurotoxic chemotherapy: hearing loss and tinnitus.BMJ Support Palliat Care. 2023 Sep;13(3):345-353. doi: 10.1136/spcare-2022-003684. Epub 2022 Jul 27. BMJ Support Palliat Care. 2023. PMID: 35896321 Free PMC article.
-
Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.J Cancer Surviv. 2018 Apr;12(2):234-245. doi: 10.1007/s11764-017-0662-8. Epub 2017 Nov 20. J Cancer Surviv. 2018. PMID: 29159795 Free PMC article.
-
[Differential diagnoses of acute bilateral hearing loss in a patient with metastatic bronchial carcinoma].HNO. 2006 Jul;54(7):553-6. doi: 10.1007/s00106-005-1317-z. HNO. 2006. PMID: 16132878 German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical